- Report
- October 2024
- 187 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- October 2024
- 199 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- June 2024
- 144 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- October 2024
- 196 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- June 2024
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- August 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- March 2025
- 291 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 224 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- March 2025
- 181 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- March 2025
- 196 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- March 2025
- 103 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 193 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- February 2025
- 213 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 250 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 250 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 250 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more